The risk of biopsy-detectable prostate cancer using the prostate cancer prevention trial risk calculator in a community setting

Yuanyuan Liang, Donna P. Ankerst, Ziding Feng, Rong Fu, Janet L. Stanford, Ian M. Thompson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Materials and methods: Risks of prostate cancer (CaP) and high-grade CaP were evaluated using the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) in an age-stratified random sample of 1,021 Caucasian and African-American men with no previous diagnosis of CaP, aged 55-74 years, residing in King County, WA, USA. Results: Median PCPTRC risks of CaP (high-grade CaP) were 15.6% (1.2%), 18.7% (2.0%), 18.5% (2.2%), and 26.4% (5.1%) for 55-59, 60-64, 65-69, and 70-74-year-old men, respectively; 25.2% of men aged 55-59 had a 25% or greater PCPTRC risk of CaP; this increased to 53.1% in men aged 70-74; 9.4% of men aged 55-59 had a 6% or greater PCPTRC risk of high-grade CaP, increasing to 44.1% in men aged 70-74. Conclusions: PCPTRC risk of CaP in a community of US males is high and confounded with overdetected cancers. In contrast, average community PCPTRC risk of high-grade disease is low and increases gradually by age and may better serve for counseling purposes.

Original languageEnglish (US)
Pages (from-to)1464-1469
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number8
DOIs
StatePublished - Nov 2013

Keywords

  • High-grade prostate cancer
  • Prostate Cancer Prevention Trial Risk Calculator (PCPTRC)
  • Prostate cancer
  • Prostate specific antigen (PSA)

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'The risk of biopsy-detectable prostate cancer using the prostate cancer prevention trial risk calculator in a community setting'. Together they form a unique fingerprint.

Cite this